Pulmonx Corporation
1.9200-0.06 (-3.03%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · LUNG · USD
Key Stats
Market Cap
78.23MP/E (TTM)
-Basic EPS (TTM)
-1.43Dividend Yield
0%Recent Filings
8-K
10-Q
Q2 FY2025 results
Pulmonx posted solid Q2 revenue growth of 14.8% y/y to $23.9M, driven by higher Zephyr Valve procedure volumes in the US (up 6.1% y/y to $14.7M) and international markets (up 32.8% y/y to $9.1M), while gross margin dipped to 72.1% from 73.7% due to geographic mix. Operating loss narrowed 5.2% y/y to $14.8M as R&D costs fell 5.5% y/y, though SG&A rose 5.5% y/y on marketing spend; net loss improved slightly to $15.2M or $(0.38) per diluted share on 40.4M shares. YTD revenue climbed 17.1% y/y to $46.4M with a 72.3% gross margin, but net loss widened to $29.6M or $(0.74) per share amid higher clinical trial costs. Cash and equivalents stood at $75.5M with $84.2M in total liquidity, supporting operations through at least the next year, while $37.1M in long-term debt matures in October 2027 at 9.0% effective rate with no principal payments until then. Revenue growth reflects steady adoption, yet reimbursement hurdles persist.
8-K
Pulmonx Q2 revenue up 15%
Pulmonx reported Q2 2025 worldwide revenue of $23.9 million, up 15% year-over-year, fueled by robust 32% international growth to $9.1 million while U.S. revenue rose a modest 6% to $14.7 million. Gross margin dipped to 72% amid higher costs, with operating expenses climbing 3% to $32.0 million, yielding a net loss of $15.2 million. The company trimmed full-year revenue guidance to $90-92 million, citing delayed U.S. traction, yet expanded treatment centers and physician training. International strength offsets domestic hurdles.
8-K
Pulmonx annual meeting results
Pulmonx Corporation's stockholders convened their 2025 Annual Meeting on May 22, with 82.79% of shares present, electing Richard M. Ferrari, Daniel P. Florin, and Steven S. Williamson as Class II directors amid significant withheld votes—Ferrari faced 11.95 million withheld versus 16.97 million for. They ratified BDO USA, P.C. as auditors for the year ending December 31, 2025, with near-unanimous support. Yet executive compensation split evenly, 14.71 million for and 14.20 million against. Shareholder sentiment divides sharply.
10-Q
Q1 FY2025 results
Pulmonx posted solid Q1 revenue growth of 19.5% y/y to $22.5M, driven by Zephyr Valve volume in the US (up 10.5% y/y to $14.2M) and international markets (up 38.3% y/y to $8.3M), yet gross margin slipped 2.2 points to 72.5% on geographic mix shifts. Operating loss held steady at $14.6M while net loss widened 5.1% y/y to $14.4M, or $(0.36) diluted EPS on 40.0M shares, with the gap to operating loss tied to $5.6M stock-based comp and $0.8M interest expense. Cash burn from operations eased to $13.2M, offset by $16.3M in investing inflows, leaving $88.7M in cash and equivalents; total debt stood at $37.2M under the CIBC term loan (9.0% rate, maturity Oct 2027) with full compliance. In April 2025, Pulmonx amended the loan to extend interest-only through maturity. Competition from alternative emphysema therapies remains a key risk.
BSX
Boston Scientific Corporation
100.30-0.67
CVRX
CVRx, Inc.
10.81+0.09
EW
Edwards Lifesciences Corporatio
82.69+0.50
INSP
Inspire Medical Systems, Inc.
75.17-2.00
LIVN
LivaNova PLC
53.34-0.52
MASI
Masimo Corporation
142.91-3.50
NVNO
enVVeno Medical Corporation
0.72+0.00
PULM
Pulmatrix, Inc.
4.88+0.01
RMD
ResMed Inc.
253.62-2.95
VMD
Viemed Healthcare, Inc.
6.54-0.32